Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of “Reduce” from Brokerages

Posted by George Bondi on Sep 5th, 2026

Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) has been given an average rating of “Reduce” by the seven analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $5.17.

TMCI has been the subject of a number of recent analyst reports. Truist Financial upped their price objective on Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. Weiss Ratings upgraded Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Finally, Wall Street Zen upgraded Treace Medical Concepts from a “sell” rating to a “hold” rating in a report on Saturday, June 20th.

Read Our Latest Research Report on Treace Medical Concepts

Insider Buying and Selling

In other news, CEO John Treace acquired 39,944 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were acquired at an average price of $4.44 per share, for a total transaction of $177,351.36. Following the completion of the transaction, the chief executive officer directly owned 7,388,383 shares of the company’s stock, valued at approximately $32,804,420.52. The trade was a 0.54% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired 108,261 shares of company stock worth $457,613 over the last ninety days. 23.42% of the stock is owned by insiders.

Hedge Funds Weigh In On Treace Medical Concepts

Several hedge funds have recently added to or reduced their stakes in TMCI. AQR Capital Management LLC purchased a new stake in Treace Medical Concepts in the 1st quarter worth about $491,000. Millennium Management LLC grew its stake in shares of Treace Medical Concepts by 35.3% during the first quarter. Millennium Management LLC now owns 444,887 shares of the company’s stock valued at $3,733,000 after buying an additional 116,114 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Treace Medical Concepts by 133,241.9% during the second quarter. Russell Investments Group Ltd. now owns 41,336 shares of the company’s stock valued at $243,000 after buying an additional 41,305 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Treace Medical Concepts by 18.6% in the second quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock worth $88,000 after buying an additional 2,362 shares during the period. Finally, Marshall Wace LLP raised its holdings in shares of Treace Medical Concepts by 256.2% in the second quarter. Marshall Wace LLP now owns 135,877 shares of the company’s stock worth $799,000 after buying an additional 97,729 shares during the period. 84.08% of the stock is currently owned by institutional investors.

Treace Medical Concepts Trading Down 1.4%

Shares of NASDAQ:TMCI opened at $4.81 on Friday. The stock’s 50-day simple moving average is $4.45 and its two-hundred day simple moving average is $3.07. The stock has a market capitalization of $312.84 million, a price-to-earnings ratio of -5.17 and a beta of 1.40. Treace Medical Concepts has a 52-week low of $1.17 and a 52-week high of $7.63. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.95 and a current ratio of 2.90.

Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.06. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. The firm had revenue of $45.38 million during the quarter, compared to analyst estimates of $44.02 million. Analysts expect that Treace Medical Concepts will post -0.83 EPS for the current year.

Treace Medical Concepts Company Profile

(Get Free Report)

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.